ArticleChemical science2016
Targeted multimodal theranostics
Article in Chemical science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Cyclodextrin nanoparticles in targeted cancer theranostics.Frontiers in pharmacology · 2023Review
- Gadofullerene inhibits the degradation of apolipoprotein B100 and boosts triglyceride transport for reversing hepatic steatosis.Science advances · 2020Article
- Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma.Molecules (Basel, Switzerland) · 2019Article
- Use of Cyclodextrins in Anticancer Photodynamic Therapy Treatment.Molecules (Basel, Switzerland) · 2018Review
- Foldable glycoprobes capable of fluorogenic crosslinking of biomacromolecules.Chemical science · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have developed a theranostic nanocomposite of metallic nanoparticles that uses two distinct fluorescence mechanisms: Förster Resonance Energy Transfer (FRET) and Metal-Enhanced Fluorescence (MEF) controlled by ligand-receptor interaction. Supramolecular assembly of the fluorophore-labeled glycoligands to cyclodextrin-capped gold nanoparticles produces a nanocomposite with a quenched fluorescence due to FRET from the fluorophore to the proximal particle. Subsequently, interaction with a selective protein receptor leads to an aggregation of the composite, reactivating the fluorescence by MEF from the distal metallic particles to fluorophores encapsulated in the aggregates. The aggregation also causes a red-shift in absorbance of the composite, thereby enhancing the production of reactive oxygen species (ROS) on red-light irradiation. Our nanocomposite has proven suitable for targeted cancer cell imaging as well as multimode therapy using both the photodynamic and drug delivery properties of the composite.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.